TRAUMA
Indometacin does not reduce the incidence of heterotopic ossification
J Bone Joint Surg Br. 2006 Dec;88(12):1613-7127 patients with displaced fractures of the acetabulum were included in this study to examine the effectiveness of indometacin in reducing the incidence of heterotopic ossification (HO). Patients were randomized to receive indometacin sustained released (75 mg) or placebo daily for 6 weeks. After 3 months, there was no significant difference between the two groups for the incidence of HO and rate of complication. Patient compliance was significantly lower in the indometacin group than in the placebo group due to side effects. From the results, indometacin does not appear to be an effective method for the reduction of HO incidence 3 months after surgery in patients with displaced fractures of the acetabulum.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
